<![CDATA[Etentamig Improves ORR/PFS in Relapsed/Refractory Multiple Myeloma]]>

Phase 3positiveEtentamigPositive

AI Analysis

Summary

Phase 3 CERVINO trial results show etentamig improved overall response rate and progression-free survival in relapsed/refractory multiple myeloma. Full results will be presented at the 23rd IMS Annual Meeting.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Improved ORR/PFS in relapsed/refractory multiple myeloma

Importance:7/10

Sentiment:

0.70

Phase 3Multiple MyelomaCERVINO TrialClinical DataOncology

Read the original article

Published by Cancer Network on September 4, 2026 4:30 PM

Read Original